AU2022260554A1 - Modulators of sortilin activity - Google Patents

Modulators of sortilin activity Download PDF

Info

Publication number
AU2022260554A1
AU2022260554A1 AU2022260554A AU2022260554A AU2022260554A1 AU 2022260554 A1 AU2022260554 A1 AU 2022260554A1 AU 2022260554 A AU2022260554 A AU 2022260554A AU 2022260554 A AU2022260554 A AU 2022260554A AU 2022260554 A1 AU2022260554 A1 AU 2022260554A1
Authority
AU
Australia
Prior art keywords
acid
halo
alkyl
propanamido
acetamido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022260554A
Other languages
English (en)
Other versions
AU2022260554A9 (en
Inventor
Manuel Javier Cases-Thomas
Mads Fuglsang KJØLBY
Paul Brian Little
Anders Nykjaer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vesper Bio ApS
Original Assignee
Insusense ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insusense ApS filed Critical Insusense ApS
Publication of AU2022260554A1 publication Critical patent/AU2022260554A1/en
Publication of AU2022260554A9 publication Critical patent/AU2022260554A9/en
Assigned to VESPER BIO APS reassignment VESPER BIO APS Amend patent request/document other than specification (104) Assignors: INSUSENSE ApS
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Secondary Cells (AREA)
  • Sawing (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2022260554A 2021-04-23 2022-04-22 Modulators of sortilin activity Abandoned AU2022260554A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21170274.1A EP4079748A1 (en) 2021-04-23 2021-04-23 Modulators of sortilin activity
EP21170274.1 2021-04-23
PCT/EP2022/060742 WO2022223805A1 (en) 2021-04-23 2022-04-22 Modulators of sortilin activity

Publications (2)

Publication Number Publication Date
AU2022260554A1 true AU2022260554A1 (en) 2023-11-02
AU2022260554A9 AU2022260554A9 (en) 2023-11-16

Family

ID=75674611

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022260554A Abandoned AU2022260554A1 (en) 2021-04-23 2022-04-22 Modulators of sortilin activity

Country Status (8)

Country Link
US (1) US20240217922A1 (cg-RX-API-DMAC7.html)
EP (2) EP4079748A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024517678A (cg-RX-API-DMAC7.html)
KR (1) KR20240000510A (cg-RX-API-DMAC7.html)
CN (1) CN117677627A (cg-RX-API-DMAC7.html)
AU (1) AU2022260554A1 (cg-RX-API-DMAC7.html)
CA (1) CA3215848A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022223805A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4471047A1 (en) * 2023-05-31 2024-12-04 Insusense ApS Modulators of sortilin activity
EP4361165A1 (en) * 2022-10-24 2024-05-01 Insusense ApS Modulators of sortilin activity
CN116143648A (zh) * 2022-12-05 2023-05-23 河北远大九孚生物科技有限公司 一种n-乙酰-l-苯丙氨酸的合成方法
EP4428124A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Modulators of sortilin activity
EP4428121A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Modulators of sortilin activity
EP4719366A1 (en) 2023-05-26 2026-04-08 Bertram Wiedenmann Sortilin inhibitors for treatment of patients with functional neuroendocrine tumors
TW202600557A (zh) * 2024-02-20 2026-01-01 日商大塚製藥股份有限公司 作為sort1抑制劑之哌啶-及嗎啉-羧酸鹽化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63183551A (ja) * 1986-10-31 1988-07-28 ファイザー・インコーポレーテッド ノルスタチンおよびノルシクロスタチンポリペプチド
DE3842067A1 (de) * 1988-12-14 1990-06-21 Hoechst Ag Enzym-hemmende aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
JPH05345754A (ja) * 1992-06-15 1993-12-27 Suntory Ltd ジペプチド誘導体およびそれを有効成分とする骨疾患の予防または治療剤
DE19546532C2 (de) * 1995-12-13 2000-04-20 Degussa Verfahren zur Gewinnung von optisch aktiven L-alpha-Aminocarbonsäuren aus entsprechenden racemischen D,L-alpha-Aminocarbonsäuren
WO2004037159A2 (en) * 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
WO2006050861A2 (en) * 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
JP2009503027A (ja) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病iiの治療のための置換エタン−1,2−ジアミン
SG176015A1 (en) 2009-05-13 2011-12-29 Gilead Sciences Inc Antiviral compounds
GB201011411D0 (en) * 2010-07-06 2010-08-18 St Georges Hosp Medical School Therapeutic compounds and their use
US9682967B2 (en) * 2013-01-28 2017-06-20 H. Lundbeck A/S N-substituted-5-substituted phthalamic acids as sortilin inhibitors
WO2015131100A1 (en) 2014-02-28 2015-09-03 The Scripps Research Institute Ligand-controlled c(sp3)-h arylation and olefination in synthesis of unnatural chiral alpha amino acids
US20160331746A1 (en) 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake

Also Published As

Publication number Publication date
CN117677627A (zh) 2024-03-08
US20240217922A1 (en) 2024-07-04
CA3215848A1 (en) 2022-10-27
WO2022223805A1 (en) 2022-10-27
KR20240000510A (ko) 2024-01-02
AU2022260554A9 (en) 2023-11-16
EP4079748A1 (en) 2022-10-26
EP4326742A1 (en) 2024-02-28
JP2024517678A (ja) 2024-04-23

Similar Documents

Publication Publication Date Title
US20240217922A1 (en) Modulators of sortilin activity
US20240294569A1 (en) Modulators of sortilin activity
TW202031659A (zh) 具抗b型肝炎病毒(hbv)活性之新穎6,7-二氫-4h-吡唑并[1,5-a]吡嗪吲哚-2-羧醯胺
JP7030776B2 (ja) アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
CN103896946A (zh) 用于预防及治疗多种自身免疫疾病的新化合物
JP2025500886A (ja) 大環状btk阻害剤
CN116745284A (zh) 作为p2x3抑制剂的酞嗪衍生物
KR20240155871A (ko) 소르틸린 의존성 질병의 치료를 위한 아미노산 기반 카바메이트 및/또는 요소
US12630558B2 (en) Pyridine derivatives as modulators of sortilin activity
EP4428121A1 (en) Modulators of sortilin activity
EP4428124A1 (en) Modulators of sortilin activity

Legal Events

Date Code Title Description
SREP Specification republished
HB Alteration of name in register

Owner name: VESPER BIO APS

Free format text: FORMER NAME(S): INSUSENSE APS

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period